Bao Feng’s, a subsidiary of Zhong Yuan, R&D team together with the group of Xuanwu Hospital, Dr. Chaodong Wang, has made a breakthrough in the field of Parkinson's disease. The relevant research results of Bao Feng's biological research team have applied for invention patents and obtained intellectual property protection.

Recently, the research group of Liqun Jiao, director of Xuanwu Hospital, Capital Medical University, and the research team of Xianyang Chen, CTO of Bao Feng Biotech, published a paper in the Journal of neurointerventional surgery, revealing that the nervonic acid molecule "Galabiosylceramide (18:1/24:1)" is a core molecular marker for differentiating cardiogenic thrombosis from atherosclerotic thrombosis.

Bao Feng Biotech, subsidiary of Zhongyuan, was certified as a “SRDI" enterprise and a National Science and Technology small medium enterprise in Beijing

In 2021, the intellectual property owner delivered a perfect answer, with 530,000 granted invention patents and 69,000 PCT international patent applications. As a "unicorn company of comprehensive brain health solution", Baofeng Bio is leading the development of the whole nervonic acid industry, and is honored to contribute to this bright report card.

Recently, the research and development team of Zhongyuan published a research paper entitled “Cognitive Improvement Effect of Nervonic Acid and Essential Fatty Acids on Rats Ingesting Acer truncatum Bunge Seed Oil Revealed by Lipidomics Approach” in Food & Function, a top journal in the field of food science and technology. This is the first study in the world to reveal the mechanism of the effect of nervonic acid and essential fatty acids on cognitive function after ingestion of Acer truncatum Bunge seed oil by lipidomics approach, which provides a scientific basis for the improvement of cognitive function by nervonic acid.

2021, as an unprecedented year for Zhongyuan Biotech, we have achieved the best substantial developments since the company was established in 2012 with our persistent endeavor to develop Zhongyuan into a sounder, stronger, and more professional cutting-edge biotechnology company of brain technology. Thanks for the companion, support and understanding of our shareholders along this journey. we are more powerful with all of you on the way moving forward! With warm greetings and best wishes for Christmas and the New Year!